Repso

leflunomide

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Repso. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Repso.

What is Repso?

Repso is a medicine that contains the active substance leflunomide. It is available as tablets (white and round: 10 mg; dark beige and triangular: 20 mg).

Repso is a ‘generic medicine’. This means that Repso is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Arava.

What is Repso used for?

Repso is used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints).

The medicine can only be obtained with a prescription.

How is Repso used?

Repso treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis. The doctor should carry out blood tests to check the patient’s liver, white-blood-cell counts and platelet counts before prescribing Repso, and regularly during treatment.

Repso treatment starts with a ‘loading dose’ of 100 mg once a day for three days, followed by a maintenance dose. The recommended maintenance dose is 10 to 20 mg once a day in patients with rheumatoid arthritis, and 20 mg once a day in patients with psoriatic arthritis. The medicine usually starts to have an effect after four to six weeks. Its effect may improve further for up to six months.

How does Repso work?

The active substance in Repso, leflunomide, is an immunosuppressant. It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation. Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply. With fewer lymphocytes, there is less inflammation, helping to control the symptoms of arthritis.

How has Repso been studied?

Because Repso is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Arava. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Repso?

Because Repso is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why has Repso been approved?

The CHMP concluded that, in accordance with EU requirements, Repso has been shown to have comparable quality and to be bioequivalent to Arava. Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk. The Committee recommended that Repso be given marketing authorisation.

Other information about Repso

The European Commission granted a marketing authorisation valid throughout the European Union for Repso to Teva Pharma B.V. on 14 March 2011. The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Repso, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Repso : EPAR - Summary for the public BG = bălgarski 2011-03-28  
Repso : EPAR - Summary for the public ES = español 2011-03-28  
Repso : EPAR - Summary for the public CS = čeština 2011-03-28  
Repso : EPAR - Summary for the public DA = dansk 2011-03-28  
Repso : EPAR - Summary for the public DE = Deutsch 2011-03-28  
Repso : EPAR - Summary for the public ET = eesti keel 2011-03-28  
Repso : EPAR - Summary for the public EL = elliniká 2011-03-28  
Repso : EPAR - Summary for the public EN = English 2011-03-28  
Repso : EPAR - Summary for the public FR = français 2011-03-28  
Repso : EPAR - Summary for the public IT = italiano 2011-03-28  
Repso : EPAR - Summary for the public LV = latviešu valoda 2011-03-28  
Repso : EPAR - Summary for the public LT = lietuvių kalba 2011-03-28  
Repso : EPAR - Summary for the public HU = magyar 2011-03-28  
Repso : EPAR - Summary for the public MT = Malti 2011-03-28  
Repso : EPAR - Summary for the public NL = Nederlands 2011-03-28  
Repso : EPAR - Summary for the public PL = polski 2011-03-28  
Repso : EPAR - Summary for the public PT = português 2011-03-28  
Repso : EPAR - Summary for the public RO = română 2011-03-28  
Repso : EPAR - Summary for the public SK = slovenčina 2011-03-28  
Repso : EPAR - Summary for the public SL = slovenščina 2011-03-28  
Repso : EPAR - Summary for the public FI = suomi 2011-03-28  
Repso : EPAR - Summary for the public SV = svenska 2011-03-28  

This EPAR was last updated on 21/04/2016 .

Authorisation details

Product details

Product details for Repso
NameRepso
Agency product numberEMEA/H/C/001222
Active substance

leflunomide

International non-proprietary name (INN) or common name

leflunomide

Therapeutic area Arthritis, RheumatoidArthritis, Psoriatic
Anatomical therapeutic chemical (ATC) code L04AA13
Generic

A generic medicine is a medicine which is similar to a medicine that has already been authorised (the 'reference medicine'). A generic medicine contains the same quantity of active substance(s) as the reference medicine. Generic and reference medicines are used at the same dose to treat the same disease, and they are equally safe and effective.

Publication details

Publication details for Repso
Marketing-authorisation holder

Teva B.V.

Revision11
Date of issue of marketing authorisation valid throughout the European Union14/03/2011

Contact address:

Teva B.V.
Swensweg 5
2031GA Haarlem
The Netherlands

Product information

Product information

30/03/2016  Repso -EMEA/H/C/001222 -IA/0020

Name Language First published Last updated
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21
Repso : EPAR - Product Information SV = svenska 2011-03-28 2016-04-21

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  
Repso : EPAR - All Authorised presentations SV = svenska 2011-03-28  

Name Language First published Last updated
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  
Repso : EPAR - Conditions imposed on member states for safe and effective use - Annex IV SV = svenska 2011-03-28  

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Leflunomide is indicated for the treatment of adult patients with:

  • active rheumatoid arthritis as a ‘disease-modifying antirheumatic drug’ (DMARD);
  • active psoriatic arthritis.

Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.

Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Repso : EPAR - Procedural steps taken and scientific information after authorisation SV = svenska 2011-09-20 2016-04-21

Initial marketing-authorisation documents

Name Language First published Last updated
Repso : EPAR - Public assessment report SV = svenska 2011-03-28  
CHMP summary of positive opinion for Repso SV = svenska 2010-12-17  

Authorised

This medicine is approved for use in the European Union

More information on Repso